Holen Sie sich die Stockscreener-App
21.17
10.09%
1.94
Schlusskurs vom Vortag:
$19.23
Offen:
$19.21
24-Stunden-Volumen:
397.08K
Relative Volume:
0.66
Marktkapitalisierung:
$400.78M
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
+30.60%
1M Leistung:
-28.82%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$15.37
$21.33
52-Wochen-Spanne:
$13.50
$39.60
Scribe Therapeutics Inc. Common Stock Stock (SCTX) Company Profile
Firmenname
Scribe Therapeutics Inc. Common Stock
Sektor
Branche
Telefon
-
Adresse
-
Compare SCTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCTX
Scribe Therapeutics Inc. Common Stock
|
21.17 | 400.78M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.89 | 128.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
212.54 | 84.85B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
765.84 | 78.85B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.91 | 51.50B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.94 | 41.36B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scribe Therapeutics Inc. Common Stock Stock (SCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-08-18 | Eingeleitet | Guggenheim | Buy |
| 2026-08-18 | Eingeleitet | Leerink Partners | Outperform |
| 2026-08-18 | Eingeleitet | Wells Fargo | Overweight |
Scribe Therapeutics Inc. Common Stock Aktie (SCTX) Neueste Nachrichten
Scribe Therapeutics Inc. Common Stock (NASDAQ: SCTX) Stock Price, News & Analysis - kalkine.ca
Scribe Therapeutics Inc. Common Stock (NASDAQ: SCTX) Stock Price, News & Analysis - Kalkine
Scribe Therapeutics (SCTX) awards 14,725 stock options to director Bleharski - Stock Titan
OrbiMed Advisors Discloses Investment in Scribe Therapeutics with 7.2% Stake - TradingView
Scribe Therapeutics Completes Initial Public Offering and Private Placement - SynBioBeta
Scribe Therapeutics raises $155.51M in IPO on Nasdaq By Investing.com - Investing.com India
Avoro lifts Scribe (NASDAQ: SCTX) stake to 3.09M shares - Stock Titan
Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO - Legal Desire
Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO - Latham & Watkins LLP
Scribe Therapeutics IPO closes as Sanofi buys 500K shares - Stock Titan
Scribe Therapeutics, In Vivo CRISPR Genetic Medicines, Files for Nasdaq IPO - TradingView
Scribe Therapeutics Announces Closing of Initial Public - GlobeNewswire
Scribe Therapeutics Closes Upsized $155.5 Million IPO and Concurrent Private Placement with Sanofi - Quiver Quantitative
Scribe Therapeutics closes $155.5M IPO at $15 per share - Investing.com
Scribe Therapeutics raises $155.51M in IPO on Nasdaq - Investing.com
Scribe Therapeutics raises $155.51M in IPO on Nasdaq By Investing.com - Investing.com Nigeria
Scribe Therapeutics (SCTX) CFO gets major option grants and family share buys - Stock Titan
Scribe Therapeutics (SCTX) awards 14,725 stock options to director James Dean Watson - Stock Titan
Scribe Therapeutics (SCTX) grants 14,725 options to Aghazadeh and Avoro entities - Stock Titan
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement - Yahoo Finance
Scribe Therapeutics (SCTX) CEO receives time- and performance-based option grants - Stock Titan
Scribe Therapeutics prices IPO at $15 per share on Nasdaq By Investing.com - Investing.com UK
IPO calendar for: - Yahoo Finance Singapore
Scribe Therapeutics prices IPO at $15 per share on Nasdaq By Investing.com - Investing.com Nigeria
Scribe Therapeutics Prices Upsized $128.7 Million Initial Public Offering and Concurrent Private Placement to Sanofi - quiverquant.com
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech - BioSpace
Scribe Therapeutics Inc. (SCTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Scribe Therapeutics (Nasdaq:SCTX)Stock Analysis - Simply Wall Street
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire
Scribe Therapeutics prices IPO at $15 per share on Nasdaq - Investing.com
Scribe Therapeutics Inc. has completed an IPO in the amount of $128.7 million. - marketscreener.com
Scribe Therapeutics prices IPO at $15, to raise $128.7M - Investing.com
Sanofi Agrees to Buy 500,000 Scribe Shares in a Private Placement - Stock Titan
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - Yahoo Finance
Scribe Therapeutics Starts IPO Effort For CRISPR Pipeline Development (SCTX) - Seeking Alpha
Scribe Therapeutics files for 7.15M share IPO at $13-$15/sh - Investing.com
Scribe Therapeutics files for 7.15M share IPO at $13-$15/sh - Investing.com Nigeria
Scribe Therapeutics files for 7.15M share IPO at $13-$15/sh - Investing.com UK
Finanzdaten der Scribe Therapeutics Inc. Common Stock-Aktie (SCTX)
Es liegen keine Finanzdaten für Scribe Therapeutics Inc. Common Stock (SCTX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Scribe Therapeutics Inc. Common Stock-Aktie (SCTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Aghazadeh Behzad | Director |
Jul 28 '26 |
Buy |
18.25 |
7,905 |
144,266 |
3,088,888 |
| GORDON CARL L | Director |
Jul 27 '26 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,348,825 |
| ORBIMED ADVISORS LLC | Director |
Jul 27 '26 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,348,825 |
| Aghazadeh Behzad | Director |
Jul 24 '26 |
Buy |
15.15 |
2,383,333 |
36,115,495 |
3,080,983 |
| Lucas Svetlana | Chief Business Officer |
Jul 23 '26 |
Buy |
15.00 |
3,000 |
45,000 |
3,000 |
| Parrot David | Chief Financial Officer |
Jul 23 '26 |
Buy |
15.00 |
2,666 |
39,990 |
1,333 |
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):